OSE Immunotherapeutics - Edison Group

Overview
Price performance
Financials
Research
Thematics

OSE Immunotherapeutics (OSE) is based in Nantes and Paris in France and is listed on the Euronext Paris exchange. It is developing immunotherapies for the treatment of solid tumours and autoimmune diseases and has established several partnerships with large pharma companies.

OSE has products in development for both immunoncology and immuno-inflammation indications. As a result, the R&D pipeline is diversified and the outlook does not depend on developments in any specific subsector.

Latest Insights

View More

Healthcare |
Flash note

18.04.24

OSE Immunotherapeutics — AbbVie deal clears antitrust hurdle

Healthcare |
Flash note

12.04.24

OSE Immunotherapeutics — Funding accelerates Tedopi clinical development

Healthcare |
Update

02.04.24

OSE Immunotherapeutics — Pipeline momentum builds into FY24

Healthcare |
Flash note

19.03.24

OSE Immunotherapeutics — One step closer to key data readouts

OSE-Immunotherapeutics_resized

Sector

Healthcare

Equity Analyst

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Analyst

Associate analyst

Jyoti Prakash

Analyst, Healthcare

Key Management

Dominique Costantini

Chairman
Nicolas Poirier

CEO

Balance Sheet

Forecast net cash (€m)

5.4

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	24.4	57.7	31.8
Relative	26.0	46.1	25.0
52 week high/low	€6.2/€2.7

Financials

OSE has announced that its licence agreement with AbbVie has cleared antitrust review and has become effective. As previously noted, this is expected to support OSE’s runway extension into 2026, past key milestones and readouts for in-house assets Tedopi (non-small cell lung cancer, US Phase III trials expected to commence in Q224) and Lusvertikimab (ulcerative colitis, Phase II readouts expected in mid-2024). Following the Federal Communications Commission (FCC) mandatory waiting period, OSE is expected to receive the negotiated US$48m upfront payment from AbbVie imminently, as part of its global licence and collaboration agreement for its pre-clinical asset OSE-230, a novel monoclonal antibody being developed for the treatment of chronic and severe inflammation. OSE is also entitled to receive up to US$665m in incremental (milestone) payments as part of the deal.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2022A	18.3	(15.0)	(18.0)	(97.28)	N/A	N/A
2023A	2.2	(19.6)	(23.2)	(118.70)	N/A	N/A
2024E	56.9	28.6	25.3	114.54	5.2	5.2
2025E	65.5	36.9	33.7	149.02	4.0	4.0

Research

edison tv

Healthcare

17.10.23

OSE Immunotherapeutics – executive interview with Nicolas Poirier, CEO

OSE-Immunotherapeutics_resized

Flash note

Healthcare

17.10.23

OSE Immunotherapeutics — Anticipation builds with positive OSE-279 data

OSE-Immunotherapeutics_resized

Healthcare

Flash note

OSE Immunotherapeutics — Collaboration bolsters upcoming Tedopi Phase III

OSE-Immunotherapeutics_resized

OSE-Immunotherapeutics_resized

Update

Healthcare

03.10.23

OSE Immunotherapeutics — Maintaining momentum after an active H123

Flash note

Healthcare

14.09.23

OSE Immunotherapeutics — Publication puts Tedopi back in the spotlight

OSE-Immunotherapeutics_resized

Flash note

Consumer

03.08.23

OSE Immunotherapeutics — Grant to weave RNA into R&D platform

OSE-Immunotherapeutics_resized

Flash note

Healthcare

06.07.23

OSE Immunotherapeutics — Lusvertikimab progressing on multiple fronts

OSE-Immunotherapeutics_resized

Flash note

Healthcare

05.07.23

OSE Immunotherapeutics — US patent to bolster Tedopi’s product portfolio

Flash note

Healthcare

26.06.23

OSE Immunotherapeutics — New diagnostic test to support Tedopi trial

OSE-Immunotherapeutics_resized

Initiation

Healthcare

24.05.23

OSE Immunotherapeutics — Milestones anticipated throughout FY23

Flash note

Healthcare

01.03.23

OSE Immunotherapeutics — Encouraging safety data for OSE-127

OSE-Immunotherapeutics_resized

Flash note

Healthcare

16.02.23

OSE Immunotherapeutics — FDA support received for Tedopi Phase III trial

Flash note

Healthcare

22.12.22

OSE Immunotherapeutics — Introducing its fifth clinical asset

Update

Healthcare

20.12.22

OSE Immunotherapeutics — €10m funding secures runway to Q323

research

Healthcare

15.12.22

OSE Immunotherapeutics — OSE-127 encouraging preclinical data in ALL

Flash note

Healthcare

03.11.22

OSE Immunotherapeutics — OSE-127 Phase II study enrolment completed

Update

Healthcare

23.09.22

OSE Immunotherapeutics — Tedopi remains focus in FY22

Flash note

Healthcare

08.06.22

OSE Immunotherapeutics — Tedopi clinical data in NSCLC and PDAC

Flash note

Healthcare

19.05.22

OSE Immunotherapeutics — First patient dosed with FR104/VEL-101

Update

Healthcare

03.05.22

OSE Immunotherapeutics — Steady progress on all fronts

Update

Healthcare

30.04.21

OSE Immunotherapeutics — Transforming into R&D powerhouse

Update

Healthcare

28.09.20

OSE Immunotherapeutics — Solid new details from Step 1 of Tedopi Ph III trial

Update

Healthcare

08.07.20

OSE Immunotherapeutics — Encouraging data from novel preclinical projects

edison tv

Healthcare

13.05.20

OSE Immunotherapeutics – executive interview

Update

Healthcare

07.04.20

OSE Immunotherapeutics — Positive Tedopi step 1, rethinking its future

Update

Healthcare

13.03.20

OSE Immunotherapeutics — Progress with key R&D assets

Update

Healthcare

30.09.19

OSE Immunotherapeutics — R&D progress triggers milestone payment windfall

Update

Healthcare

17.04.19

OSE Immunotherapeutics — A change of pace with three new clinical trials

Initiation

Healthcare

06.12.18

OSE Immunotherapeutics — Immunotherapy research engine